Cargando…

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Glioblastoma (GBM) is a highly malignant and aggressive primary brain tumor mostly prevalent in adults and is associated with a very poor prognosis. Moreover, only a few effective treatment regimens are available due to their rapid invasion of the brain parenchyma and resistance to conventional ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Na, Wei, Li, Ye, Meng, Kang, Chunsheng, You, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734213/ https://www.ncbi.nlm.nih.gov/pubmed/33329578 http://dx.doi.org/10.3389/fimmu.2020.592612

Ejemplares similares

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
por: Liu, Zefan, et al.
Publicado: (2022)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
por: Park, Jang Hyun, et al.
Publicado: (2022)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
por: Zhang, Qi-jie, et al.
Publicado: (2021)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019)

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
por: Appleton, Elizabeth, et al.
Publicado: (2021)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment
por: Luo, Hong, et al.
Publicado: (2023)

Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
por: Andersson, Patrik, et al.
Publicado: (2019)

Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy
por: Lv, Xiaohui, et al.
Publicado: (2022)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
por: Dougan, Michael
Publicado: (2017)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
por: Loo, Kimberly, et al.
Publicado: (2022)

Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
por: Li, Xueyan, et al.
Publicado: (2021)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
por: Zhu, Hua, et al.
Publicado: (2022)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
por: Georganaki, Maria, et al.
Publicado: (2018)

Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
por: Zhao, Yujie, et al.
Publicado: (2022)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
por: Zappasodi, Roberta, et al.
Publicado: (2022)

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
por: Arrieta, Víctor A., et al.
Publicado: (2023)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer
por: Cui, Yu, et al.
Publicado: (2023)

It takes two to tango: the role of tumor-associated macrophages in T cell-directed immune checkpoint blockade therapy
por: Sheban, Fadi
Publicado: (2023)

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
por: Zeng, Zhirui, et al.
Publicado: (2022)

Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade
por: Tian, Weihong, et al.
Publicado: (2023)

Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response
por: Cai, Yonghua, et al.
Publicado: (2022)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma via Single-Cell Analysis
por: Sun, Bao-Ye, et al.
Publicado: (2022)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
por: Genova, Carlo, et al.
Publicado: (2022)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness
por: Ursino, Chiara, et al.
Publicado: (2023)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
por: Jiang, Zedong, et al.
Publicado: (2021)

Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
por: Rahmy, Sharif, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a6f808nq037ldg48uivliisijb